Pre-exposure prophylaxis, or PrEP, is one of several experimental prevention interventions (including microbicides and vaccines) which could potentially provide additional modes of minimizing the risk of HIV infection. The primary goal of this proposal is to conduct a randomized blinded clinical trial evaluating the safety and efficacy of chemoprophylactic therapy using once daily tenofovir 300 mg to prevent HIV-1 acquisition in high-risk uninfected men who have sex with men (MSM). 

 

During 2006 we implemented formative research as part of preparedness phase for the implementation of a PrEP trial using antiretrovirals (tenofovir/Truvada) in two countries of the Andean Region, Ecuador and Peru. We conducted 17 focus groups with different sub cultures of men who have sex with men that may potentially enroll in a PrEP study and 2 focus groups with participants of on-going trials. We also conducted and participated in two community consultations.